Sanctura XR Related Published Studies
Well-designed clinical trials related to Sanctura XR (Trospium)
Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. [2011.02.01]
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >/= 75 years) with overactive bladder syndrome. [2011.02]
Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. [2011.01]
Once-daily trospium chloride 60 mg extended-release provides effective, long-term
relief of overactive bladder syndrome symptoms. [2011]
Comparison of intravaginal electrical stimulation and trospium hydrochloride in women with overactive bladder syndrome: a randomized controlled study. [2010.04]
Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. [2010.04]
Extended-release trospium chloride improves quality of life in overactive bladder. [2010.03]
Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. [2010.02]
Extended-release trospium chloride improves quality of life in overactive
bladder. [2010]
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. [2009.12]
Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. [2009.11]
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. [2008.03]
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. [2007.09]
Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? [2006.12]
Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. [2006.07]
Multicenter phase III trial studying trospium chloride in patients with overactive bladder. [2006.02]
Trospium chloride for the treatment of overactive bladder with urge incontinence. [2005.05]
Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. [2004.12]
Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. [2004.06]
Trospium chloride for the treatment of detrusor instability in children. [2003.11]
Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. [2003.05]
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. [2001.06]
Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. [2000.04]
Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: A pilot study. [1999]
Effects of two anticholinergic drugs, trospium chloride and biperiden, on motility and evoked potentials of the oesophagus. [1998.10]
[Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test] [1998.05]
Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. [1995.04]
Effect of the quaternary ammonium compound trospium chloride on 24 hour jejunal motility in healthy subjects. [1994.01]
Safety and tolerance of trospium chloride in the high dose range. [1993.04]
The effect of trospium chloride on oesophageal motility. [1993.02]
Ultrasound studies of the effect of trospium chloride on gall-bladder kinetics. [1992.12]
Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. [1991]
Well-designed clinical trials possibly related to Sanctura XR (Trospium)
Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. [2012]
Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? [2011.07]
Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. [2011.04]
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. [2008.05]
Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. [2006.03]
The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. [2005.05]
Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. [2005.02]
Other research related to Sanctura XR (Trospium)
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. [2011.09]
Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. [2011.04]
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. [2010.09.14]
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >/=75 years) with overactive bladder syndrome. [2010.08.06]
Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. [2010.08]
Effects of combined use of trospium chloride and melatonin on in vitro contractility of rat urinary bladder. [2010.04]
Obesity is associated with a more severe overactive bladder disease state that is
effectively treated with once-daily administration of trospium chloride extended
release. [2010]
New once-daily formulation for trospium in overactive bladder. [2010]
Comparison of intravaginal electrical stimulation and trospium hydrochloride in
women with overactive bladder syndrome: a randomized controlled study. [2010]
Pharmacokinetics of once-daily trospium chloride 60 mg extended release and
twice-daily trospium chloride 20 mg in healthy adults. [2010]
Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. [2009.12]
Extended-Release Trospium Chloride Improves Quality of Life in Overactive Bladder. [2009.10.08]
Trospium and cognition in patients with late onset Alzheimer disease. [2009.10]
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. [2009.08.29]
Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. [2009.06]
Trospium Chloride Treatment of Overactive Bladder (February) (CE). [2009.02.03]
Trospium chloride treatment of overactive bladder. [2009.02]
Role of trospium chloride in brachytherapy-related detrusor overactivity. [2008.03]
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. [2007.09]
Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. [2006.11]
Trospium chloride: the European experience. [2006.07]
Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. [2003]
Other possibly related research studies
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. [2008.09]
Urgency in overactive bladder: Translating experimental data into clinical practice. [2008.05]
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. [2008.04]
[Anticholinergic drugs in overactive bladder] [2008.01]
Pharmacologic management of overactive bladder. [2007]
Muscarinic receptor antagonists for overactive bladder. [2007.11]
Overactive bladder treatments in early phase clinical trials. [2007.07]
Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. [2007.05]
Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? [2007.06]
[How do medications used to treat urinary incontinence affect the cerebral function of the elderly?] [2007.04]
Newer agents for the management of overactive bladder. [2006.12.15]
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. [2006.12]
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. [2006.10.18]
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? [2006.11]
[Intravesical treatment of overactive bladder syndrome] [2006.10]
Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. [2006]
[Oral anticholinergics in overactive bladder] [2006.07]
Practical considerations of new drugs: new choices for old problems. [2006.04]
Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study. [2006.06]
Management of overactive bladder and urge urinary incontinence in the elderly patient. [2006.03]
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. [2006.03]
Muscarinic receptors in the bladder: from basic research to therapeutics. [2006.02]
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. [2008.08.11]
The effects of reformulation: improved therapeutic index. [2008.11]
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. [2008.11]
Persistence of antimuscarinic drug use. [2009.03]
Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? [2009.01]
Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials. [2010.07.02]
Update on the treatment of overactive bladder. [2011.07]
New strategies for medical management of overactive bladder in children. [2010.07]
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. [2011.08]
Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. [2011.02.23]
Gateways to clinical trials. [2010.07]
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. [2011.01]
Benefits and harms of pharmacologic treatment for urinary incontinence in women:
a systematic review. [2012]
|
